Clay Alspach, JD

Clay Alspach is a principal at the health policy firm Leavitt Partners. He co-founded and serves as Executive Director of the Alliance for mRNA Medicines (AMM), a global organization dedicated to advancing, and advocating for, an RNA platform approach to medicine, including protein replacements, gene editing and cell engineering strategies, immunotherapies and vaccines to treat cancer, rare disease, autoimmunity and other chronic and infectious illnesses for the benefit of patients, public health, and society. Clay also serves as Executive Director of the Association of Clinical Research Organizations (ACRO), which advocates as the collective voice of innovative clinical research and technology organizations to regulators and policymakers, educating stakeholders, and shaping policies that foster efficient, effective, and safe conduct of clinical research worldwide. Previously, Clay served as Chief Health Counsel to Chairman Fred Upton of the U.S. House Energy and Commerce Committee, where he led major bipartisan health care legislation, including the Food and Drug Administration Safety and Innovation Act (FDASIA), MACRA, Drug Quality and Security Act (DQSA), Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), and 21st Century Cures Act. He holds a B.A., cum laude, from the University of Richmond and a J.D. from the University of Texas at Austin.